BioMarin Pharmaceutical | BMRN - Operating Expenses


BioMarin Pharmaceutical reported $676.18M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amgen USD 5.9B 773M Dec/2025
Bayer EUR 10.33B 126M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Insmed USD 513.55M 109.86M Dec/2025
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
Moderna USD 1.54B 259M Dec/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 10.71B 1.32B Dec/2025
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
United Therapeutics USD 804.8M 5.79B Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025